203 related articles for article (PubMed ID: 11862382)
1. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
2. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
Steimle V; Otten LA; Zufferey M; Mach B
Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
5. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
[TBL] [Abstract][Full Text] [Related]
6. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
8. New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.
Krawczyk M; Masternak K; Zufferey M; Barras E; Reith W
Mol Cell Biol; 2005 Oct; 25(19):8607-18. PubMed ID: 16166641
[TBL] [Abstract][Full Text] [Related]
9. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.
Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ
J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692
[TBL] [Abstract][Full Text] [Related]
10. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
11. Prolonged MHC class II expression and CIITA transcription in human keratinocytes.
Takagi A; Nishiyama C; Kanada S; Niwa Y; Fukuyama K; Ikeda S; Okumura K; Ogawa H
Biochem Biophys Res Commun; 2006 Aug; 347(2):388-93. PubMed ID: 16836979
[TBL] [Abstract][Full Text] [Related]
12. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
[TBL] [Abstract][Full Text] [Related]
13. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency.
Villard J; Lisowska-Grospierre B; van den Elsen P; Fischer A; Reith W; Mach B
N Engl J Med; 1997 Sep; 337(11):748-53. PubMed ID: 9287230
[TBL] [Abstract][Full Text] [Related]
14. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
16. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
17. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
19. Mutation in the class II trans-activator leading to a mild immunodeficiency.
Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition effect of CIITA anti-sense cDNA on the expression of MHCII molecules of Hela cells].
Guo R; Zou P; Fan HH; Cui L; Cao YL; Zheng B; Gao L; Gao F; Lu HZ
Zhonghua Xue Ye Xue Za Zhi; 2003 Dec; 24(12):636-9. PubMed ID: 14761611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
